$1.08 Billion is the total value of FRAZIER MANAGEMENT LLC's 34 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 14.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARQT | Sell | ARCUTIS BIOTHERAPEUTICS INC | $230,170,000 | -24.5% | 8,434,232 | -20.0% | 21.23% | -13.2% |
PHAT | PHATHOM PHARMACEUTICALS INC | $197,258,000 | -9.9% | 5,827,415 | 0.0% | 18.19% | +3.6% | |
PASG | PASSAGE BIO INC | $66,322,000 | -24.3% | 5,009,219 | 0.0% | 6.12% | -12.9% | |
MIRM | MIRUM PHARMACEUTICALS INC | $61,672,000 | -12.8% | 3,566,912 | 0.0% | 5.69% | +0.3% | |
TBIO | Sell | TRANSLATE BIO INC | $57,360,000 | +59.4% | 2,082,789 | -4.6% | 5.29% | +83.2% |
IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $55,631,000 | +33.8% | 2,137,999 | +62.8% | 5.13% | +53.9% |
KRYS | Sell | KRYSTAL BIOTECH INC | $53,576,000 | -22.3% | 787,876 | -12.0% | 4.94% | -10.7% |
PCVX | VAXCYTE INC | $51,988,000 | +14.0% | 2,309,554 | 0.0% | 4.79% | +31.0% | |
TARS | Sell | TARSUS PHARMACEUTICALS INC | $41,069,000 | -33.5% | 1,417,157 | -26.1% | 3.79% | -23.6% |
TRILLIUM THERAPEUTICS INC | $30,275,000 | -9.4% | 3,123,107 | 0.0% | 2.79% | +4.2% | ||
ANAB | ANAPTYSBIO INC | $23,329,000 | +20.3% | 899,700 | 0.0% | 2.15% | +38.3% | |
ALPN | ALPINE IMMUNE SCIENCES INC | $23,143,000 | -15.1% | 2,571,450 | 0.0% | 2.13% | -2.4% | |
SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $20,400,000 | -36.4% | 1,188,135 | -17.2% | 1.88% | -26.9% |
STRO | SUTRO BIOPHARMA INC | $18,616,000 | -18.3% | 1,001,421 | 0.0% | 1.72% | -6.1% | |
ISEE | IVERIC BIO INC | $16,056,000 | +2.1% | 2,544,500 | 0.0% | 1.48% | +17.4% | |
KDNY | New | CHINOOK THERAPEUTICS INC | $15,532,000 | – | 1,100,000 | +100.0% | 1.43% | – |
AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $15,166,000 | – | 2,283,966 | +100.0% | 1.40% | – |
FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $15,085,000 | -1.1% | 1,501,000 | 0.0% | 1.39% | +13.7% | |
RGNX | REGENXBIO INC | $13,673,000 | +13.9% | 351,954 | 0.0% | 1.26% | +30.9% | |
MTEM | MOLECULAR TEMPLATES INC | $10,745,000 | -38.0% | 1,374,047 | 0.0% | 0.99% | -28.8% | |
GRTS | GRITSTONE BIO INC | $9,412,000 | -3.2% | 1,030,878 | 0.0% | 0.87% | +11.3% | |
EPIX | ESSA PHARMA INC | $9,046,000 | -1.7% | 316,616 | 0.0% | 0.83% | +13.0% | |
ACRS | Sell | ACLARIS THERAPEUTICS INC | $6,510,000 | -62.9% | 370,733 | -46.7% | 0.60% | -57.4% |
EPZM | EPIZYME INC | $6,144,000 | -4.6% | 739,369 | 0.0% | 0.57% | +9.7% | |
APTX | Sell | APTINYX INC | $5,330,000 | -44.3% | 1,883,244 | -41.0% | 0.49% | -35.9% |
SRRK | SCHOLAR ROCK HLDG CORP | $4,508,000 | -43.0% | 156,000 | 0.0% | 0.42% | -34.4% | |
FRLN | FREELINE THERAPEUTICS HLDGSsponsored ads | $4,483,000 | -33.7% | 550,000 | 0.0% | 0.41% | -23.9% | |
ALNA | ALLENA PHARMACEUTICALS | $4,329,000 | -6.5% | 3,330,373 | 0.0% | 0.40% | +7.5% | |
BLU | BELLUS HEALTH INC NEW | $4,030,000 | -18.6% | 1,296,743 | 0.0% | 0.37% | -6.3% | |
SRRA | SIERRA ONCOLOGY INC | $3,949,000 | +13.0% | 202,803 | 0.0% | 0.36% | +30.0% | |
AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $3,891,000 | -25.5% | 578,104 | 0.0% | 0.36% | -14.3% | |
IMVT | Sell | IMMUNOVANT INC | $2,685,000 | -67.0% | 254,000 | -50.0% | 0.25% | -62.1% |
GRTX | GALERA THERAPEUTICS INC | $2,369,000 | +11.4% | 241,000 | 0.0% | 0.22% | +27.5% | |
NABRIVA THERAPEUTICS PLC | $575,000 | -18.7% | 425,650 | 0.0% | 0.05% | -7.0% | ||
ITRM | Exit | ITERUM THERAPEUTICS PLC | $0 | – | -1,538,316 | -100.0% | -0.17% | – |
CRDF | Exit | CARDIFF ONCOLOGY INC | $0 | – | -293,500 | -100.0% | -0.22% | – |
ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -1,437,028 | -100.0% | -1.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
APTINYX INC | 15 | Q4 2021 | 16.9% |
KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2022-11-14 |
13F-HR | 2022-08-10 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-08 |
13F-HR | 2021-11-12 |
13F-HR | 2021-08-11 |
13F-HR | 2021-05-12 |
13F-HR | 2021-02-11 |
13F-HR | 2020-11-12 |
13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.